CY1126115T1 - Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων - Google Patents

Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων

Info

Publication number
CY1126115T1
CY1126115T1 CY20231100360T CY231100360T CY1126115T1 CY 1126115 T1 CY1126115 T1 CY 1126115T1 CY 20231100360 T CY20231100360 T CY 20231100360T CY 231100360 T CY231100360 T CY 231100360T CY 1126115 T1 CY1126115 T1 CY 1126115T1
Authority
CY
Cyprus
Prior art keywords
antibodies
lag
combination
tumor treatment
antibody
Prior art date
Application number
CY20231100360T
Other languages
English (en)
Inventor
Alan J. Korman
Nils Lonberg
David J. Fontana
Andres A. Gutierrez
Mark J. Selby
Katherine E. Lewis
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1126115T1 publication Critical patent/CY1126115T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Παρέχονται μέθοδοι για κλινική θεραπεία όγκων (π.χ., προηγμένων συμπαγών όγκων) χρησιμοποιώντας αντι-LAG-3 αντίσωμα σε συνδυασμό με αντι-PD-1 αντίσωμα.
CY20231100360T 2013-09-20 2023-07-25 Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων CY1126115T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361880606P 2013-09-20 2013-09-20
US201462014471P 2014-06-19 2014-06-19
PCT/US2014/056277 WO2015042246A1 (en) 2013-09-20 2014-09-18 Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP14786389.8A EP3046939A1 (en) 2013-09-20 2014-09-18 Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP16197459.7A EP3178849B1 (en) 2013-09-20 2014-09-18 Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors

Publications (1)

Publication Number Publication Date
CY1126115T1 true CY1126115T1 (el) 2023-11-15

Family

ID=51743546

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100634T CY1121723T1 (el) 2013-09-20 2019-06-19 Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY20231100360T CY1126115T1 (el) 2013-09-20 2023-07-25 Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20191100634T CY1121723T1 (el) 2013-09-20 2019-06-19 Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων

Country Status (24)

Country Link
US (4) US10081681B2 (el)
EP (4) EP3178849B1 (el)
JP (3) JP6595458B2 (el)
KR (4) KR20230008255A (el)
CN (2) CN105793287B (el)
AU (3) AU2014323523B2 (el)
BR (2) BR122023024195A2 (el)
CA (1) CA2924524A1 (el)
CY (2) CY1121723T1 (el)
DK (2) DK3178849T3 (el)
EA (1) EA036902B1 (el)
ES (2) ES2728578T3 (el)
FI (1) FI3508502T3 (el)
HR (2) HRP20230603T1 (el)
HU (2) HUE044730T2 (el)
IL (3) IL244547B (el)
LT (2) LT3508502T (el)
MX (2) MX2016003103A (el)
PL (2) PL3508502T3 (el)
PT (2) PT3178849T (el)
RS (2) RS64268B1 (el)
SG (2) SG10201802264PA (el)
SI (2) SI3178849T1 (el)
WO (1) WO2015042246A1 (el)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP3178849B1 (en) 2013-09-20 2019-03-20 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
RS59480B1 (sr) 2013-12-12 2019-12-31 Shanghai hengrui pharmaceutical co ltd Pd-1 antitelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primena
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
ES2902369T3 (es) * 2014-01-28 2022-03-28 Bristol Myers Squibb Co Anticuerpos anti-LAG-3 para tratar neoplasias malignas hemáticas
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN106103484B (zh) * 2014-03-14 2021-08-20 诺华股份有限公司 针对lag-3的抗体分子及其用途
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
MY178347A (en) 2014-07-17 2020-10-08 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
RS60631B1 (sr) 2014-11-21 2020-09-30 Bristol Myers Squibb Co Antitela protiv cd73 i njihova upotreba
GB201500374D0 (en) * 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
WO2016176503A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
WO2016176504A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
ES2835866T3 (es) * 2015-05-12 2021-06-23 Hoffmann La Roche Procedimientos terapéuticos y de diagnóstico para el cáncer
SG10201913500TA (en) 2015-05-29 2020-03-30 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
RU2733033C2 (ru) 2015-06-24 2020-09-28 Иммодьюлон Терапьютикс Лимитед Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака
KR20180040138A (ko) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
US10544224B2 (en) * 2015-07-14 2020-01-28 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor
AR105444A1 (es) * 2015-07-22 2017-10-04 Sorrento Therapeutics Inc Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
JP6840127B2 (ja) * 2015-07-29 2021-03-10 ノバルティス アーゲー がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
KR20180034588A (ko) 2015-07-30 2018-04-04 마크로제닉스, 인크. Pd-1-결합 분자 및 그것의 사용 방법
US20190010231A1 (en) * 2015-08-07 2019-01-10 Pieris Pharmaceuticals Gmbh Novel fusion polypeptide specific for lag-3 and pd-1
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
CR20180318A (es) 2015-12-14 2018-09-19 Macrogenics Inc Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
EA201891983A8 (ru) * 2016-03-04 2020-05-28 Бристол-Майерс Сквибб Компани Комбинированная терапия антителами к cd73
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
TWI822521B (zh) 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
AR108516A1 (es) 2016-05-18 2018-08-29 Boehringer Ingelheim Int Moléculas de anticuerpo anti-pd1 y anti-lag3 para el tratamiento del cáncer
EP3458053B1 (en) 2016-05-20 2021-12-08 Biohaven Pharmaceutical Holding Company Ltd. Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
TWI784957B (zh) 2016-06-20 2022-12-01 英商克馬伯有限公司 免疫細胞介素
PT3476399T (pt) 2016-06-23 2022-05-31 Jiangsu Hengrui Medicine Co Anticorpo lag-3, fragmento de ligação a antigénio deste e aplicação farmacêutica deste
CN109414490A (zh) * 2016-07-01 2019-03-01 小利兰·斯坦福大学理事会 抑制性免疫受体抑制方法和组合物
TW202246349A (zh) 2016-10-11 2022-12-01 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
CN117567623A (zh) 2016-10-13 2024-02-20 正大天晴药业集团股份有限公司 抗lag-3抗体及组合物
US11359018B2 (en) 2016-11-18 2022-06-14 Symphogen A/S Anti-PD-1 antibodies and compositions
MX2019006340A (es) 2016-12-07 2019-11-07 Agenus Inc Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
JP7167041B2 (ja) 2017-02-10 2022-11-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体
TWI786096B (zh) * 2017-03-15 2022-12-11 學校法人兵庫醫科大學 癌症免疫療法之新穎生物標記
EP3595715A1 (en) * 2017-03-17 2020-01-22 CureVac AG Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
MA50056A (fr) 2017-03-31 2020-02-05 Bristol Myers Squibb Co Procédés de traitement de tumeur
LT3606946T (lt) 2017-04-03 2022-10-25 F. Hoffmann-La Roche Ag Anti-pd-1 antikūno imunokonjugatai su mutantiniu il-2 arba su il-15
JP2020513009A (ja) * 2017-04-05 2020-04-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療
KR102346336B1 (ko) 2017-04-05 2022-01-04 에프. 호프만-라 로슈 아게 Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
MX2019011945A (es) 2017-04-05 2019-11-28 Boehringer Ingelheim Int Terapia de combinacion contra cancer.
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
AU2018253948A1 (en) 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy with an anti-AXL Antibody-Drug Conjugate
JP7402691B2 (ja) 2017-04-20 2023-12-21 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ２５抗体薬物複合体による併用療法
US20220135670A1 (en) * 2017-04-27 2022-05-05 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
CA3060581A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR102376863B1 (ko) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. 메소텔린 결합 단백질
CN108864287B (zh) * 2017-05-16 2022-08-30 上海恒润达生生物科技股份有限公司 一种靶向Mesothelin的嵌合抗原受体并对其两种修饰的方法及其用途
CN110869392A (zh) * 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
WO2018217940A2 (en) * 2017-05-24 2018-11-29 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
JP2020522691A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌａｇ−３陽性腫瘍の処置
KR20200010500A (ko) 2017-05-30 2020-01-30 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체, pd-1 경로 억제제, 및 면역요법제의 조합을 포함하는 조성물
CA3065304A1 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
BR112019024291A2 (pt) 2017-06-09 2020-07-28 Providence Health & Services-Oregon utilização de cd39 e de cd103 para a identificação de células t tumorais humanas reativas para o tratamento do câncer
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
CA3073733A1 (en) 2017-08-30 2019-03-07 Phanes Therapeutics, Inc. Anti-lag-3 antibodies and uses thereof
CN111247169A (zh) 2017-10-15 2020-06-05 百时美施贵宝公司 治疗肿瘤的方法
TW201916890A (zh) * 2017-10-17 2019-05-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｐｄ－１抗體和抗ｌａｇ－３抗體聯合在製備治療腫瘤的藥物中的用途
CN115925943A (zh) * 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
WO2019129137A1 (zh) * 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN109970856B (zh) * 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
US11655295B2 (en) 2018-01-18 2023-05-23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-LAG-3 antibody and use thereof
EP3768720A4 (en) 2018-03-20 2022-01-05 Wuxi Biologics Ireland Limited NEW ANTI-LAG-3 ANTIBODY POLYPEPTIDE
CN112236456B (zh) * 2018-03-20 2023-12-22 上海药明生物技术有限公司 新型双特异性pd-1/lag-3抗体分子
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
CN111971306A (zh) 2018-03-30 2020-11-20 百时美施贵宝公司 治疗肿瘤的方法
JP2021524449A (ja) 2018-05-23 2021-09-13 アーデーセー セラピューティクス ソシエテ アノニム 分子アジュバント
CN113166972A (zh) * 2018-06-11 2021-07-23 耶鲁大学 新型免疫检查点抑制剂
WO2020002905A1 (en) 2018-06-25 2020-01-02 Immodulon Therapeutics Limited Cancer therapy
US11945864B2 (en) 2018-06-29 2024-04-02 Y-Biologics Inc. Monoclonal antibody specifically binding to LAG-3 and use thereof
BR112021000511A2 (pt) * 2018-07-26 2021-04-06 Bristol-Myers Squibb Company Terapia de combinação de lag-3 para o tratamento de câncer
EP3849606A4 (en) * 2018-09-13 2022-06-29 Merck Sharp & Dohme Corp. Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
AU2019361124A1 (en) * 2018-10-19 2021-06-03 Bristol-Myers Squibb Company Combination therapy for melanoma
US20210347889A1 (en) * 2018-11-05 2021-11-11 Merck Sharp & Dohme Corp. Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer
JP2022512855A (ja) * 2018-11-07 2022-02-07 メルク・シャープ・アンド・ドーム・コーポレーション 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
JP2022532490A (ja) * 2019-05-13 2022-07-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
KR20220016157A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 조합 요법
CN112079925A (zh) * 2019-06-13 2020-12-15 上海健信生物医药科技有限公司 靶向lag-3的抗体和双特异性抗体及其用途
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021055994A1 (en) 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
JP2022553851A (ja) 2019-11-08 2022-12-26 ブリストル－マイヤーズ スクイブ カンパニー 黒色腫の処置のためのｌａｇ－３アンタゴニスト
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
CN112852740A (zh) * 2019-11-27 2021-05-28 深圳市菲鹏生物治疗股份有限公司 Car-t细胞和检测方法
WO2021133653A1 (en) * 2019-12-23 2021-07-01 Macrogenics, Inc. Therapy for the treatment of cancer
KR20220131279A (ko) 2020-01-21 2022-09-27 상하이 헨리우스 바이오테크, 인크. 항lag3단일 클론 항체 및 그 제조 방법과 응용
CN114605544B (zh) * 2020-06-05 2023-08-01 北京天广实生物技术股份有限公司 Lag3抗体及其用途
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
BR112023003427A2 (pt) 2020-08-28 2023-03-21 Bristol Myers Squibb Co Terapia com antagonista de lag-3 para carcinoma hepatocelular
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
EP4232019A1 (en) 2020-10-23 2023-08-30 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
AU2021411486A1 (en) 2020-12-28 2023-06-29 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022188867A1 (zh) * 2021-03-12 2022-09-15 中山康方生物医药有限公司 提高含有免疫球蛋白Fc片段的药物的安全性的方法
WO2022212400A1 (en) 2021-03-29 2022-10-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
BR112023022097A2 (pt) 2021-06-07 2023-12-19 Agonox Inc Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
WO2023051621A1 (zh) * 2021-09-29 2023-04-06 中山康方生物医药有限公司 抗lag3抗体、药物组合物及用途
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023077090A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
CN115845051B (zh) * 2022-12-28 2024-02-02 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗肝癌中的应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
MX9605365A (es) 1994-05-06 1997-12-31 Roussy Inst Gustave Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica y anticuerpos ant-idiotipo.
CA2227334A1 (en) 1995-07-21 1997-02-06 Applied Research Systems Ars Holding N.V. Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
AU2071597A (en) 1996-03-07 1997-09-22 Eastman Chemical Company Near infrared fluorescent security thermal transfer printing and marking ribbons
AU728911B2 (en) 1996-11-28 2001-01-18 Institut Gustave Roussy Mutants of the LAG-3 proteins, products for the expression of these mutants and use
CA2272130C (en) 1996-11-29 2007-10-23 Applied Research Systems Ars Holding N.V. Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
KR100856446B1 (ko) 1998-12-23 2008-09-04 화이자 인크. Ｃｔｌａ－４에 대한 인간 단일클론 항체
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
CA2383424C (en) 1999-08-23 2011-02-15 Gordon Freeman Novel b7-4 molecules and uses therefor
US6808710B1 (en) 1999-08-23 2004-10-26 Genetics Institute, Inc. Downmodulating an immune response with multivalent antibodies to PD-1
EP2829609A1 (en) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
EP1401866A2 (en) 2001-02-22 2004-03-31 Institut Pasteur Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20020146753A1 (en) 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
EP1295895B1 (en) 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
WO2003025202A2 (en) 2001-09-19 2003-03-27 Alexion Pharmaceuticals, Inc. Engineered templates and their use in single primer amplification
WO2003088808A2 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2476518A1 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
FI2206517T3 (fi) 2002-07-03 2023-10-19 Ono Pharmaceutical Co Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita
EP2322202A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune diseases
US20050009136A1 (en) 2003-02-19 2005-01-13 Dyax Corporation PAPP-A ligands
US20060240024A1 (en) 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
EP1678195A4 (en) 2003-10-08 2008-04-23 The Feinstein Inst Medical Res TECHNIQUES AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA OF BETA CELLS
CA2546054C (en) 2003-12-10 2014-05-13 Medarex, Inc. Interferon alpha antibodies and their uses
SV2006001990A (es) 2004-01-09 2006-01-30 Pfizer Anticuerpos contra madcam
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
EP1967529A1 (en) 2004-07-20 2008-09-10 Symphogen A/S Anti-rhesus D recombinant polyclonal antibody and methods of manufacture
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
US20090252741A1 (en) 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
ZA200703154B (en) 2004-10-01 2008-09-25 Medarex Inc Methods of treating CD30 positive lymphomas
MX2007004176A (es) 2004-10-06 2007-06-15 Mayo Foundation B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer.
US20080279865A1 (en) 2005-03-23 2008-11-13 Pfizer, Inc., Pfizer Products, Inc. Therapy of Prostate Cancer With Ctla-4 Antibodies and Hormonal Therapy
LT2439273T (lt) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
US7850965B2 (en) 2005-12-05 2010-12-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
JP2009539413A (ja) 2006-06-12 2009-11-19 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド エフェクター機能を有する単鎖多価結合タンパク質
CN101490085A (zh) * 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
JP5382692B2 (ja) 2006-07-10 2014-01-08 学校法人藤田学園 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
JP5456658B2 (ja) 2007-03-30 2014-04-02 メディミューン，エルエルシー 抗体製剤
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
PT2201100E (pt) 2007-09-14 2016-06-03 Univ Brussel Vrije Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
SI2376535T1 (sl) 2008-12-09 2017-07-31 F. Hoffmann-La Roche Ag Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t
US20110007023A1 (en) 2009-07-09 2011-01-13 Sony Ericsson Mobile Communications Ab Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
AR077756A1 (es) 2009-07-15 2011-09-21 Genentech Inc Anticuerpos especificos para bacterias gram-positivas
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
DK2593475T3 (en) 2010-07-14 2016-05-30 Merck Sharp & Dohme Anti-ADDL monoclonal antibody and uses thereof
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
US9217039B2 (en) 2010-11-01 2015-12-22 Symphogen A/S Anti-HER3 antibodies and compositions
LT2699264T (lt) 2011-04-20 2018-07-10 Medimmune, Llc Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
EP3378489A1 (en) * 2011-10-26 2018-09-26 Elanco Tiergesundheit AG Monoclonal antibodies and methods of use
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
AU2014230741B2 (en) 2013-03-15 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
JP2016531907A (ja) * 2013-08-02 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． 免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ
EP3178849B1 (en) 2013-09-20 2019-03-20 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
ES2902369T3 (es) 2014-01-28 2022-03-28 Bristol Myers Squibb Co Anticuerpos anti-LAG-3 para tratar neoplasias malignas hemáticas
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
KR20200010500A (ko) 2017-05-30 2020-01-30 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체, pd-1 경로 억제제, 및 면역요법제의 조합을 포함하는 조성물
CA3065304A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
JP2020522691A (ja) 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌａｇ−３陽性腫瘍の処置
BR112021000511A2 (pt) 2018-07-26 2021-04-06 Bristol-Myers Squibb Company Terapia de combinação de lag-3 para o tratamento de câncer
AU2019361124A1 (en) 2018-10-19 2021-06-03 Bristol-Myers Squibb Company Combination therapy for melanoma

Also Published As

Publication number Publication date
EP3046939A1 (en) 2016-07-27
JP2016531849A (ja) 2016-10-13
IL290295A (en) 2022-04-01
RS64268B1 (sr) 2023-07-31
CN112516302A (zh) 2021-03-19
LT3178849T (lt) 2019-06-10
JP7163260B2 (ja) 2022-10-31
KR20210141789A (ko) 2021-11-23
HUE062317T2 (hu) 2023-10-28
US20220185892A1 (en) 2022-06-16
JP2023002678A (ja) 2023-01-10
KR20230008255A (ko) 2023-01-13
AU2023200557A1 (en) 2023-03-02
AU2020203056A1 (en) 2020-05-28
SG10201802264PA (en) 2018-05-30
KR20160055269A (ko) 2016-05-17
JP2020011984A (ja) 2020-01-23
PT3178849T (pt) 2019-06-11
CA2924524A1 (en) 2015-03-26
EP3178849B1 (en) 2019-03-20
FI3508502T3 (fi) 2023-06-06
KR20240033088A (ko) 2024-03-12
CN105793287B (zh) 2020-10-02
EP3508502A1 (en) 2019-07-10
US11274152B2 (en) 2022-03-15
EA036902B1 (ru) 2021-01-13
HRP20190774T1 (hr) 2019-06-14
US20200062845A1 (en) 2020-02-27
CN105793287A (zh) 2016-07-20
EP3178849A1 (en) 2017-06-14
EP4249065A3 (en) 2023-11-15
SI3508502T1 (sl) 2023-07-31
PL3178849T3 (pl) 2019-08-30
SI3178849T1 (sl) 2019-06-28
CY1121723T1 (el) 2020-07-31
BR122023024195A2 (pt) 2023-12-26
MX2016003103A (es) 2016-05-26
AU2014323523A1 (en) 2016-04-07
MX2021002728A (es) 2021-07-16
EP4249065A2 (en) 2023-09-27
SG11201601763SA (en) 2016-04-28
PL3508502T3 (pl) 2023-07-17
PT3508502T (pt) 2023-06-22
AU2014323523B2 (en) 2020-02-20
IL272149A (en) 2020-03-31
ES2728578T3 (es) 2019-10-25
EA201690617A1 (ru) 2016-07-29
DK3508502T3 (da) 2023-07-31
JP6595458B2 (ja) 2019-10-23
BR112016005816A2 (pt) 2017-09-19
HUE044730T2 (hu) 2019-11-28
ES2947575T3 (es) 2023-08-11
IL244547B (en) 2020-02-27
AU2020203056B2 (en) 2022-11-10
US10081681B2 (en) 2018-09-25
IL272149B (en) 2022-03-01
LT3508502T (lt) 2023-07-10
US20210009692A1 (en) 2021-01-14
IL244547A0 (en) 2016-04-21
RS58705B1 (sr) 2019-06-28
WO2015042246A1 (en) 2015-03-26
US20160222116A1 (en) 2016-08-04
HRP20230603T1 (hr) 2023-09-29
DK3178849T3 (da) 2019-07-01
EP3508502B1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
CY1126115T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY1119799T1 (el) Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου
CY1121907T1 (el) Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
CY1123858T1 (el) Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων
CY1124299T1 (el) Συνδυαστικες θεραπειες που περιλαμβανουν μορια αντισωματων κατα toy lag-3
CY1124096T1 (el) Αντισωματα τα οποια στοχευουν αντιγονο ωριμανσης β-κυτταρων και μεθοδοι χρησης
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
CY1119510T1 (el) Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης
CY1121934T1 (el) Αντισωματα anti-fcrn
BR112016003394A2 (pt) usos de um antagonista de pd-1 e um agonista do gitr e de um anticorpo biespecífico ou fragmento de ligação do antígeno do mesmo, e, combinação farmacêutica
NZ741324A (en) Anti-cd47 antibodies and methods of use
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
EA201591801A1 (ru) Лекарственные конъюгаты антител
TR201907240T4 (tr) Bir anti cd20 antikorunun bir btk inhibitörü ile kombinasyon tedavisi.
UY35399A (es) Conjugados de fármacos con anticuerpos
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
MX2018002166A (es) Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn